DURECT Corporation to Present Breakthrough Epigenetic Therapies at Major Healthcare Conference

DURECT Corporation's Upcoming Presentation at Oppenheimer Conference

DURECT Corporation, a California-based biopharmaceutical company listed on Nasdaq under the ticker symbol DRRX, has announced that its President and CEO, James E. Brown, will be showcasing the company's innovative research at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. This significant event is set to take place virtually from February 11 to 12, 2025.

Presentation Details

The presentation is scheduled for February 11, 2025, from 2:00 PM to 2:30 PM ET on Track 5 of the conference. DURECT management is planning to engage with investors through one-on-one meetings, giving participants an opportunity to discuss the company's direction and scientific advancements in detail. Interested investors are encouraged to get in touch with their Oppenheimer representatives for more personalized interactions.

About DURECT Corporation

DURECT is pioneering epigenetic therapies aimed at addressing critical health challenges, particularly those associated with dysregulated DNA methylation. The company's leading candidate, Larsucosterol, is designed to inhibit DNA methyltransferases, enzymes linked to conditions such as alcohol-associated hepatitis (AH), which poses a significant risk of acute organ injury. Larsucosterol's intervention targets the elevated levels of these enzymes, which are often correlated with hypermethylation in patients.

Currently, Larsucosterol is in clinical studies aimed at treating AH. The FDA has recognized its potential, granting it both Fast Track and Breakthrough Therapy designations that could accelerate its path towards approval. Additionally, DURECT is exploring Larsucosterol’s efficacy for treating metabolic dysfunction-associated steatohepatitis (MASH).

Beyond Larsucosterol, DURECT has made strides with POSIMIR®, a bupivacaine solution that utilizes the innovative SABER® platform for infiltration pain management. POSIMIR has received FDA approval, underscoring DURECT's commitment to providing healthcare solutions that reduce reliance on opioids.

Challenges and Opportunities Ahead

While the outlook for DURECT's therapies is promising, the company faces various challenges typical for businesses in the biopharmaceutical sector. There is always the risk that clinical trials might not yield positive results or that additional studies may be mandated by regulatory bodies before final approvals are granted. Furthermore, DURECT must continue to optimize its financial health, ensuring it can sustain its operations and development programs throughout the lengthy drug development process.

Conclusion

The Oppenheimer 35th Annual Healthcare Life Sciences Conference is a critical platform for DURECT Corporation to present its advancements in the field of epigenetic therapy. Stakeholders, including investors and healthcare professionals, will have the opportunity to gain insights into how DURECT plans to address significant medical challenges through innovative therapeutic approaches.

For additional information or to track DURECT’s progress in the biopharmaceutical landscape, interested individuals can visit their official website at DURECT Corporation or follow them on X (formerly Twitter) at DURECTCorp.